New Alzheimer's drug research
Published 13 April 2009
New research suggests that the drug CPHPC successfully interferes with the build up of Amyloid in the brains of people with Alzheimer’s and does not have side effects.
The University College London (UCL) research will be published in Proceedings of the National Academy of Sciences.
Dr Susanne Sorensen
Head of Research
Alzheimer's Society
ENDS
Alzheimer's Society
Alzheimer's Society is the leading care and research charity for people with all forms of dementia and their carers. It provides information and education, support for carers, and quality day and home care. It funds medical and scientific research and campaigns for improved health and social services and greater public understanding of dementia.
The Alzheimer's Society provides a national help line on 0845 3000 336 and website alzheimers.org.uk. Please include this information in any publication that uses these comments.
For more information contact: Press Office 0207 423 3595 press@alzheimers.org.uk
'A key characteristic of Alzheimer's disease is the clumping together of proteins in the brain. It's very exciting that this drug could potentially interfere with this process, but it's too early to say how much it will benefit people with the disease.
This research is an important step forward because it shows the drug is safe to use in people with Alzheimer's. It provides a green flag for longer and larger studies to investigate if this drug can treat the symptoms, or even slow the progression of this devastating disease. One million people will develop dementia in the next 10 years. We must act now to improve care for today and find a cure for tomorrow.'
Dr Susanne Sorensen
Head of Research
Alzheimer's Society
ENDS
Alzheimer's Society
Alzheimer's Society is the leading care and research charity for people with all forms of dementia and their carers. It provides information and education, support for carers, and quality day and home care. It funds medical and scientific research and campaigns for improved health and social services and greater public understanding of dementia.
The Alzheimer's Society provides a national help line on 0845 3000 336 and website alzheimers.org.uk. Please include this information in any publication that uses these comments.
For more information contact: Press Office 0207 423 3595 press@alzheimers.org.uk
